Vis enkel innførsel

dc.contributor.advisorSmåbrekke, Lars
dc.contributor.authorHaukaas, Jeroen Martin van Zuiden
dc.date.accessioned2024-09-11T04:05:10Z
dc.date.available2024-09-11T04:05:10Z
dc.date.issued2024-05-14en
dc.description.abstractPembrolizumab monotherapy for non-small cell lung cancer (NSCLC) was deemed not cost-effective due to limited data, high uncertainty regarding long term results and a considerable budget impact. However, due to confidential price agreements it was approved in 2017, as first-line treatment for metastatic NSCLC that expresses PD-L1 ≥ 50 %. Given potential discrepancies between clinical efficacy and real-world effectiveness due to differing treatment guidelines and inclusion criteria, it’s uncertain whether the treatment is truly cost-effective, especially since projections are based on immature data. Our objectives are to (1) re-evaluate the economic feasibility of pembrolizumab in treating lung cancer within the Norwegian healthcare framework with real world data; (2) to identify the possible variables contributing to the gap between its efficacy in controlled studies and its effectiveness in a clinical setting and (3) to provide a framework for assessing the cost-effectiveness of treatments with immature data.en_US
dc.identifier.urihttps://hdl.handle.net/10037/34657
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universitetno
dc.publisherUiT The Arctic University of Norwayen
dc.rights.holderCopyright 2024 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subject.courseIDFAR-3911
dc.subjectPembrolizumaben_US
dc.subjectPharmacoeconomicsen_US
dc.subjectReal-world dataen_US
dc.subjectNSCLCen_US
dc.subjectCanceren_US
dc.subjectLung canceren_US
dc.titleUsing real world data for pharmacoeconomic assessments - a case studyen_US
dc.typeMastergradsoppgaveno
dc.typeMaster thesisen


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)